Biotechnology company Scribe Therapeutics (SCTX.US) applies for US IPO with plans to raise up to $75 million.

Biotechnology company Scribe Therapeutics submitted an initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Thursday, aiming to raise up to $75 million. Scribe Therapeutics is a clinical-stage biotechnology company dedicated to developing therapies based on in vivo CRISPR technology, with the goal of extending healthy lifespan through disease prevention, focusing initially on cardiovascular and metabolic diseases. Its lead candidate drug, STX-1150, uses an epigenetic silencing strategy to achieve long-lasting reduction of low-density lipoprotein cholesterol (LDL-C) by inhibiting PCSK9 expression without altering DNA sequences. This drug has been approved by the Australian Therapeutic Goods Administration (TGA) and is currently undergoing its first human clinical trials in the country, with preliminary clinical data expected in the first half of 2027. Two other pipeline products, STX-1200 and STX-1400, utilize the company's XE gene editing technology targeting lipoprotein(a) and triglycerides, as they are important pathogenic factors in atherosclerotic cardiovascular diseases. These projects are partially funded by the California Institute for Regenerative Medicine (CIRM) and are expected to enter Phase I clinical trials in 2027 and 2028. Founded in 2017 and headquartered in Alameda, California, the company plans to list on the Nasdaq with the stock symbol "SCTX." Leerink Partners, Goldman Sachs, Guggenheim Securities, and William Blair are the joint underwriters for this transaction.